SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-005331
Filing Date
2023-03-01
Accepted
2023-03-01 07:07:51
Documents
14
Period of Report
2023-03-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K omga-20230301.htm   iXBRL 8-K 58000
2 EX-99.1 omga-ex99_1.htm EX-99 230718
3 GRAPHIC img220583725_0.jpg GRAPHIC 16872
  Complete submission text file 0000950170-23-005331.txt   446539

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT omga-20230301.xsd EX-101.SCH 2489
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT omga-20230301_lab.xml EX-101.LAB 14018
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT omga-20230301_pre.xml EX-101.PRE 11507
8 EXTRACTED XBRL INSTANCE DOCUMENT omga-20230301_htm.xml XML 4703
Mailing Address 20 ACORN PARK DRIVE CAMBRIDGE MA 02140
Business Address 20 ACORN PARK DRIVE CAMBRIDGE MA 02140 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40657 | Film No.: 23689682
SIC: 2836 Biological Products, (No Diagnostic Substances)